Consensus report of a joint NCI thoracic malignancies steering committee: FDA workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to the inception of "master protocols" in lung cancer.

摘要: On February 2, 2012, the National Cancer Institute (NCI) sponsored a 2-day workshop with NCI Thoracic Malignancies Steering Committee and Food Drug Administration to bring together leading academicians, clinicians, industry government representatives identify challenges potential solutions in clinical development of novel targeted therapies for lung cancer. Measures success are rapidly evolving from scientific regulatory perspective objectives this were achieve initial consensus on high priority biomarker-driven trial designed assess activity agents molecularly defined cancer subsets facilitate generation data approval these new therapies. Additionally, meeting focused identification barriers conduct such strategies overcome those barriers. The “Lung Master Protocols” recently launched by direct outcome workshop.